EX-10.2



 Exhibit 10.2 

EXECUTION COPY 
  

 
 EXCHANGE AGREEMENT 

among 
 EVOLENT HEALTH,
INC. 
 EVOLENT HEALTH LLC 

and 
 THE CLASS B MEMBERS
OF EVOLENT HEALTH LLC 
 Dated as of June 4, 2015 
  

 







 TABLE OF CONTENTS 

 

							
	 	 	 	  	Page	 
	 ARTICLE 1 DEFINED TERMS
	  	 	2	  
			
	 Section 1.01.
	 	 Definitions
	  	 	2	  
			
	 Section 1.02.
	 	 Other Definitional and Interpretative Provisions
	  	 	4	  
		
	 ARTICLE 2 EXCHANGE
	  	 	4	  
			
	 Section 2.01.
	 	 Exchanges
	  	 	4	  
			
	 Section 2.02.
	 	 Adjustment
	  	 	7	  
			
	 Section 2.03.
	 	 Expiration
	  	 	8	  
			
	 Section 2.04.
	 	 Reservation of Class A Shares; Listing
	  	 	8	  
			
	 Section 2.05.
	 	 Recapitalization
	  	 	8	  
			
	 Section 2.06.
	 	 Removal of Impediments to Exchange
	  	 	8	  
		
	 ARTICLE 3 TRANSFER RESTRICTIONS
	  	 	8	  
			
	 Section 3.01.
	 	 General Restrictions on Transfer
	  	 	8	  
			
	 Section 3.02.
	 	 Legends
	  	 	9	  
			
	 Section 3.03.
	 	 Permitted Transferees
	  	 	9	  
		
	 ARTICLE 4 OTHER AGREEMENTS; MISCELLANEOUS
	  	 	9	  
			
	 Section 4.01.
	 	 Expenses
	  	 	9	  
			
	 Section 4.02.
	 	 Notices
	  	 	10	  
			
	 Section 4.03.
	 	 Permitted Transferees
	  	 	10	  
			
	 Section 4.04.
	 	 Severability
	  	 	10	  
			
	 Section 4.05.
	 	 Counterparts
	  	 	11	  
			
	 Section 4.06.
	 	 Entire Agreement; No Third Party Beneficiaries
	  	 	11	  
			
	 Section 4.07.
	 	 Further Assurances
	  	 	11	  
			
	 Section 4.08.
	 	 Dispute Resolution
	  	 	11	  
			
	 Section 4.09.
	 	 Governing Law
	  	 	11	  
			
	 Section 4.10.
	 	 Consent to Jurisdiction
	  	 	11	  
			
	 Section 4.11.
	 	 WAIVER OF JURY TRIAL
	  	 	11	  
			
	 Section 4.12.
	 	 Amendments; Waivers
	  	 	11	  
			
	 Section 4.13.
	 	 Assignment
	  	 	12	  
			
	 Section 4.14.
	 	 Tax Treatment
	  	 	12	  
			
	 Section 4.15.
	 	 Effective Date
	  	 	12	  








 EXCHANGE AGREEMENT 

among 
 EVOLENT HEALTH,
INC. 
 EVOLENT HEALTH LLC 

and 
 THE CLASS B MEMBERS
OF EVOLENT HEALTH LLC 
 EXCHANGE AGREEMENT, dated as of June 4, 2015 (this “Agreement”), among Evolent Health,
Inc., a Delaware corporation (“Evolent Health, Inc.”), Evolent Health LLC, a Delaware limited liability company (the “Company”) and the holders from time to time of Class B common units in the Company listed on
Exhibit A hereto (collectively, the “Class B Members”). Capitalized terms used but not simultaneously defined are defined in or by reference to Section 1.01. 

W I T N E S S E T H: 
 WHEREAS,
in connection with the initial public offering of Class A Shares (the “IPO”), Evolent Health, Inc. intends to consummate the transactions described below and in the Registration Statement on Form S-1 originally filed with the
Commission on May 4, 2015, as amended (Registration No. 333-203852); 
 WHEREAS, in connection with the IPO (i) the preferred
units of the Company will be converted into common units of the Company, (ii) the second amended and restated limited liability company agreement of the Company will be further amended and restated to establish two classes of equity consisting
of the Class A common units to be held by Evolent Health, Inc. and Class B common units to be initially held by TPG Eagle Holdings, L.P. (“TPG”), The Advisory Board Company (“The Advisory Board”) and Ptolemy
Capital, LLC (“Ptolemy”) in the amounts set forth in Exhibit A hereto, (iii) the shares of preferred stock of Evolent Health Holdings, Inc., which is the predecessor to Evolent Health, Inc., will be converted into common
stock of Evolent Health Holdings, Inc. and (iv) pursuant to a series of share exchanges and contributions, Evolent Health, Inc. will issue Class A Shares to certain pre-merger stockholders of Evolent Health Holdings, Inc. and TPG Eagle BL,
LLC, a Delaware limited liability company and an affiliate of TPG (“TPG Eagle”), and Class B Shares to the Class B Members in an amount equal to the number of Class B common units issued to such Class B Member, and pursuant to
a series of mergers, Evolent Health Holdings, Inc. and TPG Eagle will merge with and into Evolent Health, Inc. with Evolent Health, Inc. continuing as the surviving entity and, in connection with such mergers, Evolent Health, Inc. will issue
Class A Shares to the other pre-merger stockholders of Holdings; 
 WHEREAS, the parties hereto desire to provide for the possible
future exchange following the IPO of Class B common units (together with a transfer to Evolent Health, Inc. of the corresponding number of Class B Shares), for Class A Shares on the terms and subject to the conditions set forth herein;

 WHEREAS, neither Evolent Health, Inc. nor the Company shall have any obligation to acquire from a Class B Member any Class B common units
and Class B Shares unless such Class B Member exercises its Exchange Right with respect to such Class B common units and Class B Shares in accordance herewith; and 







 WHEREAS, the parties intend that an Exchange consummated hereunder be treated for U.S. federal
income tax purposes, to the extent permitted by law, as a taxable sale of Class B common units and Class B Shares. 
 NOW, THEREFORE,
in consideration of the mutual covenants and undertakings contained herein and for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto hereby agree as follows: 

ARTICLE 1 
 DEFINED TERMS 

Section 1.01. Definitions. As used in this Agreement, the following terms have the following meanings: 

“Agreement” is defined in the preamble. 

“Business Combination Transaction” is defined in the Amended and Restated Certificate of Incorporation of Evolent Health,
Inc. 
 “Business Day” means any day except a Saturday, Sunday, or other day on which commercial banks in New York, New
York are authorized by law to close. 
 “Class A common units” is defined in the Operating Agreement. 

“Class A Shares” means shares of Class A common stock, par value $0.01 per share, of Evolent Health, Inc. 

“Class B common units” is defined in the Operating Agreement. 

“Class B Members” is defined in the preamble. 

“Class B Shares” means shares of Class B common stock, par value $0.01 per share, of Evolent Health, Inc. 

“Closing” means the closing of an Exchange pursuant to Section 2.01. 

“Code” means the Internal Revenue Code of 1986, as amended. 

“Commission” means the U.S. Securities and Exchange Commission or any successor thereto. 

“Company” is defined in the preamble. 

“Evolent Health, Inc.” is defined in the preamble. 

“Exchange,” when used as a noun, means an exchange by a Class B Member of one or more Class B common units (together with a
transfer to Evolent Health, Inc. of the corresponding number of Class B Shares), for Class A Shares. “Exchange,” when used as a verb, and “Exchanging,” when used as an adjective, shall have correlative
meanings. 
 “Exchange Rate” means the number of Class A Shares for which a Class B common unit (together with the
corresponding number of Class B Shares) is entitled to be Exchanged, as provided in Section 2.01(a), subject to adjustment as provided in Section 2.02. 

  
 2 








 “Exchange Request” means a written notice to the Company, delivered at least
three Business Days in advance of the Closing of the Exchange, setting forth the number of Class B common units (and the corresponding number of Class B Shares) to be Exchanged. 

“Exchange Right” means the right of a Class B Member to Exchange from time to time one or more Class B common units (together
with the corresponding number of Class B Shares). 
 “Governmental Entity” means any court, administrative agency,
regulatory body, commission, or other governmental authority, board, bureau, or instrumentality, domestic or foreign, and any subdivision thereof. 

“IPO” is defined in the recitals. 

“Liens” means any and all liens, charges, security interests, options, claims, mortgages, pledges, proxies, voting trusts or
agreements, obligations, understandings or arrangements, or other restrictions on title or transfer of any nature whatsoever. 

“Notice” is defined in Section 4.02. 

“Operating Agreement” means the Third Amended and Restated Limited Liability Company Agreement of the Company dated as of the
date hereof, as such agreement may be amended from time to time. 
 “Permitted Transferee” is defined in the Operating
Agreement. 
 “Person” means any natural person, corporation, limited partnership, general partnership, limited liability
company, joint stock company, joint venture, association, company, estate, trust, bank trust company, land trust, business trust or other organization, whether or not a legal entity, custodian, trustee-executor, administrator, nominee or entity in a
representative capacity, and any government or agency or political subdivision thereof. 
 “Ptolemy” is defined in the
recitals. 
 “Registration Rights Agreement” means the Registration Rights Agreement dated as of the date hereof by and
among Evolent Health, Inc., the Class B Members and the other parties thereto. 
 “Restricted Class A Shares” is
defined in Section 3.01. 
 “Securities Act” means the U.S. Securities Act of 1933, as amended. 

“Stockholders Agreement” means the Stockholders Agreement dated as of the date hereof by and among Evolent Health, Inc., TPG
BDH, TPG Eagle, The Advisory Board, UPMC and the other parties thereto. 
 “Tax Receivables Agreement” means the tax
receivables agreement, by and among Evolent Health, Inc., TPG BDH, The Advisory Board, UPMC, Ptolemy and certain holders of Class A Shares. 

“The Advisory Board” is defined in the recitals. 

“TPG” is defined in the recitals. 

“TPG BDH” means TPG Growth II BDH L.P., a Delaware limited partnership. 

  
 3 








 “TPG Eagle” is defined in the recitals. 

“UPMC” means UPMC, a Pennsylvania nonprofit corporation. 

Section 1.02. Other Definitional and Interpretative Provisions. The words “hereof,” “herein” and
“hereunder” and words of like import used in this Agreement shall refer to this Agreement as a whole and not to any particular provision of this Agreement. The headings and captions herein are included for convenience of reference only and
shall be ignored in the construction or interpretation hereof. References to Articles, Sections and Exhibits are to Articles, Sections and Exhibits of this Agreement unless otherwise specified. Any capitalized term used in any Exhibit and not
otherwise defined therein has the meaning ascribed to such term in this Agreement. Any singular term in this Agreement shall be deemed to include the plural, and any plural term the singular. Whenever the words “include,”
“includes” or “including” are used in this Agreement, they shall be deemed to be followed by the words “without limitation,” whether or not they are in fact followed by those words or words of like import.
“Writing,” “written” and comparable terms refer to printing, typing and other means of reproducing words (including electronic media) in a visible form. References to any agreement or contract are to that agreement or contract as
amended, restated, modified or supplemented from time to time in accordance with the terms thereof. References to any Person include the successors and permitted assigns of that Person. References from or through any date mean, unless otherwise
specified, from and including or through and including, respectively. 
 ARTICLE 2 

EXCHANGE 
 Section 2.01.
Exchanges. (a) Permissible Exchanges. (i) Upon the terms and subject to the conditions of this Article 2, each Class B Member may, at any time and from time to time, elect to Exchange in one or more Exchanges up to 100% of
the Class B Member’s Class B common units (together with the corresponding number of Class B Shares) by delivering an Exchange Request to the Company, with a copy to Evolent Health, Inc. 

(ii) Each Exchange Request shall set forth the number of Class B common units (together with the corresponding number of Class B Shares)
such Class B Member wishes to Exchange at the applicable Closing. If any Exchange Request is made in connection with a contemplated underwritten offering of Class A Shares and such underwritten offering includes any option being granted to the
underwriters to acquire an additional number of Class A Shares in connection with such offering, then (A) each Exchange Request related to Class B common units to be Exchanged for Class A Shares that will be included in such
underwritten offering shall also specify the maximum number of additional Class B common units that the Class B Member desires to have Exchanged in the event that such option is exercised (it being understood that (x) the party exercising such
option may have the right to do so in part, in which case the additional Class B common units Exchanged in connection with such offering will be limited to the amount necessary to fulfill the delivery obligation with respect to the Class A
Shares that are actually to be acquired upon exercise of such option, (y) the allocation of Class A Shares to be acquired pursuant to an exercise of any such option among the Persons participating in such offering may not be known at the
time of the delivery of the original Exchange Request, in which case the maximum number of additional Class B common units to potentially be Exchanged will be communicated to Evolent Health, Inc. pursuant to a supplement to the Exchange Request
delivered promptly following the time at which such determination is made, which supplement to the Exchange Request need not be delivered five Business Days in advance of the applicable Exchange and (z) Evolent Health, Inc. shall have no
obligation to issue or deliver any Class A Shares in the event that the number of Class A Shares to be acquired upon exercise of such option is greater than the number of Class A Shares that is required by this Agreement to be


  
 4 








 
delivered in the Exchange) and (B) the Closing of the Exchange of any additional Class B common units to fulfill a Class B Member’s delivery obligation with respect to the Class A
Shares that are to be acquired upon exercise of any such option will occur immediately prior to the time that delivery of such Class A Shares is to be made. 

(iii) Each Class B Member shall represent in the Exchange Request that such Class B Member owns or will own the Class B common units and
Class B Shares to be delivered at the applicable Closing pursuant to Section 2.01(d)(i) and Section 2.01(d)(ii), free and clear of all Liens, except as set forth therein and other than transfer restrictions imposed by or under
applicable securities laws and this Agreement and the Operating Agreement, and, if there are any Liens identified in the Exchange Request, such Class B Member shall covenant that such Class B Member will deliver at the applicable Closing evidence
reasonably satisfactory to the Company that all such Liens (other than transfer restrictions imposed by or under applicable securities laws and this Agreement and the Operating Agreement) have been released. 

(iv) Upon delivery to the Company, no Exchange Request may be revoked less than three Business Days prior to the scheduled Closing of the
applicable Exchange (and the Company shall have received notice of such revocation no later than such third Business Day) unless the Class B Member that has delivered such Exchange Request reimburses all out-of-pocket costs incurred by Evolent
Health, Inc. or the Company with respect to such requested Exchange. 
 (v) No Exchange shall be permitted (and, if attempted, shall be void
ab initio) if, in the good faith determination of the Company, such Exchange would pose a material risk that the Company would be a “publicly traded partnership” as defined in Section 7704 of the Code; provided that an Exchange will
not be prohibited on this basis so long as the Company continues to satisfy the “private placements” safe harbor pursuant to Section 1.7704-1 of the Treasury Regulations promulgated under such Section 7704 of the Code. 

(vi) Each Exchange pursuant to this Section 2.01(a) shall be at the Exchange Rate in effect at the applicable Closing. 

(b) Closing. (i) If an Exchange Request has been delivered pursuant to Section 2.01(a)(i), then (subject to
Section 2.01(c)) the Closing of such Exchange shall occur within three Business Days of the delivery of such Exchange Request or such later time as requested by the Exchanging Class B Member. 

(ii) If Evolent Health, Inc. enters into an agreement to consummate a Business Combination Transaction, Evolent Health, Inc. shall give each
Class B Member at least five Business Days’ notice of the closing thereof and, upon the written request of a Class B Member, Evolent Health, Inc. shall cause such agreement to (and shall not enter into any such agreement unless it does)
provide that such Class B Member shall be entitled to Exchange its Class B common units (together with the corresponding number of Class B Shares) immediately prior to the closing of the Business Combination Transaction in order for such Class
B Member to be able to receive the amount and type of consideration payable pursuant to such Business Combination Transaction to holders of Class A Shares. If any Person commences a tender offer or exchange offer for any of the outstanding
shares of Evolent Health, Inc.’s stock, upon the written request of a Class B Member, Evolent Health, Inc. shall entitle such Class B Member, at the request of such Class B Member, to Exchange its Class B common units (together with the
corresponding number of Class B Shares) immediately prior to and contingent upon the consummation of such tender offer or exchange offer in order for such Class B Member to participate in such tender offer or exchange offer. Notwithstanding
anything to the contrary in the foregoing, in the event that board of directors of Evolent Health, Inc. approves a Business Combination Transaction and determines in good faith that such Business Combination Transaction involves a bona fide third
party and is not for the primary purpose of causing an Exchange hereunder, then upon at least five Business Days’ notice, the mandatory Exchange 

  
 5 








 
of all outstanding Class B common units (together with the corresponding number of Class B Shares) shall occur in accordance with the following sentence. The Closing for any Exchange in
which Class A Shares are delivered occurring pursuant to this Section 2.01(b)(ii) shall occur immediately prior to, but remain subject to the consummation immediately after of, the Business Combination Transaction, tender offer or exchange
offer, as applicable, and such Exchange shall be null and void if such Business Combination Transaction, tender offer or exchange offer, as applicable, shall fail to be consummated. 

(iii) Upon receiving notice of an Exchange Request under Section 2.01(a)(i), the Company may elect to cause Evolent Health, Inc. to
effect the Exchange under Section 2.01(d) and deliver to the Exchanging Class B Member the number of Class A Shares that such Class B Member is entitled to receive in the Exchange. In all other cases, the Company shall effect the Exchange
and, at the time of the Closing of any such Exchange, Evolent Health, Inc. shall contribute to the Company the number of Class A Shares that such Class B Member is entitled to receive in the Exchange. 

(iv) Upon the occurrence of a Closing, (A) all rights of the Exchanging Class B Member as holder of the Class B common units (and
corresponding number of Class B Shares) being Exchanged shall terminate, (B) the Class B Shares delivered at the Closing shall be automatically cancelled on the books and records of Evolent Health, Inc. and shall no longer be deemed
to be issued and outstanding capital stock of Evolent Health, Inc., (C) the Class B common units delivered at the Closing to the Company or Evolent Health, Inc., as applicable, shall automatically be cancelled on the books and records of the
Company and shall no longer be deemed to be issued and outstanding membership interests of the Company, and (D) such Exchanging Class B Member, or such other Person in whose name such Exchanging Class B Member has requested the shares be
registered, shall be treated for all purposes as the holder of any Class A Shares delivered at the Closing. 
 (v) The Class A
Shares to be received in the Exchange shall be registered in such names and in such denominations as the Exchanging Class B Member shall request in writing not later than one Business Day prior to Closing. 

(c) Closing Conditions. (i) The obligation of any of the parties to consummate an Exchange pursuant to this Section 2.01
shall be subject to the condition that there shall be no injunction, restraining order or decree of any nature of any Governmental Entity that is then in effect that restrains or prohibits the Exchange. 

(ii) The obligation of the Company and Evolent Health, Inc. to consummate an Exchange pursuant to this Section 2.01 shall be subject to
(A) the delivery by the Exchanging Class B Member of the items specified in clauses (i), (ii) and (iii) of Section 2.01(d) and (B) the good faith determination by Evolent Health, Inc. that such Exchange would not be
prohibited by applicable law or regulation and would not violate any contract, commitment, agreement, instrument, arrangement, understanding, obligation or undertaking to which the Company or Evolent Health, Inc. is subject. 

(d) Closing Deliveries. At or prior to each Closing, with respect to each Class B Member that requests the Exchange contemplated for
such Closing: 
 (i) to the extent that such Class B Member’s Class B common units are certificated, such Class B Member
shall deliver to the Company or Evolent Health, Inc., as applicable, one or more certificates representing the number of Class B common units specified in the applicable Exchange Request (or an affidavit of loss in lieu thereof in customary form,
without any requirement to post a bond or furnish any other security), accompanied by security transfer powers, in form reasonably satisfactory to the Company or Evolent Health, Inc., as applicable, duly executed in blank by such Class B Member or
such Class B Member’s duly authorized attorney, to be Exchanged based on the Exchange Rate in effect at the applicable Closing; 

  
 6 








 (ii) to the extent such Class B Member’s Class B Shares are
certificated, such Class B Member shall deliver to the Company or Evolent Health, Inc., as applicable, one or more certificates representing the number of Class B Shares specified in the applicable Exchange Request (or an affidavit of loss in
lieu thereof in customary form, without any requirement to post a bond or furnish any other security), accompanied by security transfer powers, in form reasonably satisfactory to the Company or Evolent Health, Inc., as applicable, duly executed in
blank by such Class B Member or such Class B Member’s duly authorized attorney; 
 (iii) such Class B Member shall
represent in writing, and at the Company or Evolent Health, Inc.’s request deliver confirmatory evidence reasonably satisfactory to the Company or Evolent Health, Inc., as applicable, that no Liens exist on the Class B common units and
Class B Shares delivered pursuant to Sections 2.01(d)(i) and 2.01(d)(ii) (other than transfer restrictions imposed by or under applicable securities laws, the Operating Agreement and this Agreement), or that any such Liens have been released;

 (iv) if such Class B Member delivers to the Company or Evolent Health, Inc., pursuant to Section 2.01(d)(i) or
2.01(d)(ii), a certificate representing a number of Class B common units or Class B Shares that is greater than the number of Class B common units or Class B Shares specified in the applicable Exchange Request, the Company or Evolent
Health, Inc. will deliver to such Class B Member certificates representing the excess Class B common units or Class B Shares, as applicable; and 

(v) The Company or Evolent Health, Inc., as applicable, shall deliver or cause to be delivered to such Class B Member the
number of Class A Shares that such Class B Member is entitled to receive in the Exchange, registered in such names and such denominations as such Class B Member requested pursuant to Section 2.01(b)(iv). 

(e) Tax Treatment. Unless otherwise required by an applicable change in law, the parties hereto acknowledge and agree that the
Exchanges, if effected by the Company, will be treated as “disguised sales” of the Class B common units to Evolent Health, Inc. under Section 707 of the Code. 

Section 2.02. Adjustment. On the date hereof, the Exchange Rate shall be 1 for 1. The Exchange Rate shall be adjusted accordingly
if there is: (i) any subdivision (by any unit or stock split, unit or stock distribution, reclassification, reorganization, recapitalization or otherwise) or combination (by reverse unit or stock split, reclassification, reorganization,
recapitalization or otherwise) of the Class B common units or Class B Shares or any similar event, in each case that is not accompanied by an identical subdivision or combination of the Class A Shares; or (ii) any subdivision (by any stock
split, stock dividend or distribution, reclassification, reorganization, recapitalization or otherwise) or combination (by reverse stock split, reclassification, reorganization, recapitalization or otherwise) of the Class A Shares or any
similar event, in each case that is not accompanied by an identical subdivision or combination of the Class B common units and Class B Shares. If there is any reclassification, reorganization, recapitalization or other similar transaction in which
the Class A Shares are converted or changed into another security, securities or other property, then upon any subsequent Exchange, an Exchanging Class B Member shall be entitled to receive the amount of such security, securities or other
property that such Exchanging Class B Member would have received if such Exchange had occurred immediately prior to the effective date of such reclassification, reorganization, recapitalization or other similar transaction, taking into account any
adjustment as a result of any subdivision (by any split, distribution or dividend, reclassification, reorganization, recapitalization or otherwise) or combination (by reverse split, reclassification, recapitalization or otherwise) of such security,
securities or other property that occurs after the effective time of such reclassification, reorganization, recapitalization or other similar transaction. For the avoidance of doubt, if there is any reclassification, reorganization, recapitalization
or other similar 

  
 7 








 
transaction in which the Class A Shares are converted or changed into another security, securities or other property, this Section 2.02 shall continue to be applicable, mutatis
mutandis, with respect to such security or other property. 
 Section 2.03. Expiration. In the event that the Company is
dissolved, liquidated or wound up pursuant to the Operating Agreement or otherwise, any Exchange Right shall expire upon final distribution of the assets of the Company pursuant to the terms and conditions of the Operating Agreement. 

Section 2.04. Reservation of Class A Shares; Listing. Evolent Health, Inc. shall at all times reserve and keep available out
of its authorized but unissued Class A Shares, solely for the purpose of issuance upon an Exchange, the maximum number of Class A Shares as shall be issuable upon Exchange of all outstanding Class B common units and Class B Shares;
provided that nothing contained herein shall be construed to preclude Evolent Health, Inc. from satisfying its obligations in respect of any such Exchange by delivery of purchased Class A Shares (which may or may not be held in the treasury of
Evolent Health, Inc.). If any Class A Shares require registration with or approval of any Governmental Entity under any federal or state law before such Class A Shares may be issued upon an Exchange, Evolent Health, Inc. shall use
reasonable efforts to cause such Class A Shares to be duly registered or approved, as the case may be. Evolent Health, Inc. shall list and use its reasonable efforts to maintain the listing of the Class A Shares required to be delivered
upon any such Exchange prior to such delivery upon the national securities exchange upon which the outstanding Class A Shares are listed at the time of such Exchange (it being understood that any such shares may be subject to transfer
restrictions under applicable securities laws). Evolent Health, Inc. covenants that all Class A Shares issued upon an Exchange will, upon issuance, be validly issued, fully paid and non-assessable. 

Section 2.05. Recapitalization. This Agreement shall apply to the Class B common units held by the Class B Members and their
Permitted Transferees as of the date hereof, as well as any Class B common units hereafter acquired by a Class B Member and its Permitted Transferees. This Agreement shall apply to, mutatis mutandis, and all references to “Class B common
units” shall be deemed to include, any security, securities or other property of the Company that may be issued in respect of, in exchange for or in substitution of Class B common units, by reason of any distribution or dividend, split, reverse
split, combination, reclassification, reorganization, recapitalization, merger, exchange (other than an Exchange) or other transaction. 

Section 2.06. Removal of Impediments to Exchange. The Company and Evolent Health, Inc. shall use reasonable best efforts to remove
any impediment that in the good faith judgment of the Company and Evolent Health, Inc. would cause any Exchange to be prohibited by applicable law or regulation or that would cause any Exchange to violate any contract, commitment, agreement,
instrument, arrangement, understanding, obligation or undertaking to which the Company or Evolent Health, Inc. is subject. 
 ARTICLE 3 

TRANSFER RESTRICTIONS 

Section 3.01. General Restrictions on Transfer. (a) Each Class B Member understands and agrees that the Class A Shares
received by such Class B Member in any Exchange (any such Class A Shares, “Restricted Class A Shares”) may not be transferred except in compliance with the Securities Act, any other applicable securities or “blue
sky” laws, and the terms and conditions of this Agreement. 

  
 8 








 (b) Without limitation of Section 3.01(a), each Class B Member understands and agrees that,
unless exchanged pursuant to an effective registration statement under the Securities Act, the Restricted Class A Shares are restricted securities under the Securities Act and the rules and regulations promulgated thereunder. Each Class B
Member agrees that it shall not Transfer any Restricted Class A Shares (or solicit any offers in respect of any Transfer of any Restricted Class A Shares), except in compliance with the Securities Act, any other applicable securities or
“blue sky” laws, and the terms and conditions of this Agreement. 
 (c) Any attempt to transfer any Restricted Class A Shares
not in compliance with this Agreement shall be void ab initio, and Evolent Health, Inc. shall not, and shall cause any transfer agent not to, give any effect in Evolent Health, Inc.’s stock records to such attempted transfer. 

Section 3.02. Legends. (a) In addition to any other legend that may be required, subject to Section 3.02(b), each
certificate for Restricted Class A Shares issued to a Class B Member (or any of such Class B Member’s Permitted Transferees) shall bear a legend in substantially the following form: 

THIS SECURITY HAS NOT BEEN REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED, OR ANY NON-U.S. OR STATE SECURITIES LAWS AND MAY NOT
BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED EXCEPT IN COMPLIANCE THEREWITH. 
 (b) If any Restricted Class A Share is eligible to
be sold pursuant to Rule 144(b)(1) under the Securities Act (or any successor provision), upon the written request of the holder thereof, accompanied (if Evolent Health, Inc. shall so request) by an opinion of counsel reasonably acceptable to
Evolent Health, Inc., Evolent Health, Inc. shall issue to such holder a new certificate evidencing such Restricted Class A Share without the legend required by Section 3.02(a) endorsed thereon. 

Section 3.03. Permitted Transferees. Subject to this Article 3, each Class B Member acquiring Restricted Class A Shares
may at any time transfer any or all of its Restricted Class A Shares to one or more of its Permitted Transferees or to any other Person in a transaction not in contravention of, and in accordance with, the Operating Agreement, so long as the
transfer to such transferee is in compliance with the Securities Act and any other applicable securities or “blue sky” laws. 

ARTICLE 4 
 OTHER AGREEMENTS;
MISCELLANEOUS 
 Section 4.01. Expenses. Each party hereto shall bear its own expenses in connection with the consummation of
any of the transactions contemplated hereby, whether or not any such transaction is ultimately consummated, except that Evolent Health, Inc. shall bear any transfer taxes, stamp taxes or duties, or other similar taxes in connection with, or arising
by reason of, any Exchange and Evolent Health, Inc. shall promptly cooperate in all filings required to be made under the Hart-Scott-Rodino Antitrust Improvement Act of 1976, as amended, in connection with any Exchange (but Evolent Health, Inc.
shall not be obligated to bear, and shall be reimbursed by the applicable Class B Member for, the expenses of any such filing or of any information request from any Governmental Entity relating thereto); provided, however, that if any
certificate is to be issued pursuant to Section 2.01(d)(v) in a name other than that of the Class B Member that requested the Exchange, then the Person or Persons requesting the issuance thereof shall pay to Evolent Health, Inc. the amount of
any transfer taxes, stamp taxes or duties, or other similar taxes in connection with, or arising by reason of, such Exchange or shall establish to the reasonable satisfaction of Evolent Health, Inc. that such tax has been paid or is not payable.


  
 9 








 Section 4.02. Notices. All notices, requests, consents and other communications
hereunder (each, a “Notice”) to any party shall be in writing and shall be delivered in person or sent by facsimile (provided a copy is thereafter promptly delivered as provided in this Section 4.02), email or nationally
recognized overnight courier, addressed to such party at the address, facsimile number or email address set forth in Exhibit A hereto, or below with respect to Evolent Health, Inc., or such other address or facsimile number as may hereafter be
designated in writing by such party to the other parties: 
 if to Evolent Health, Inc., to: 

800 N. Glebe Road, Suite 500 

Arlington, VA 22203 
 Telephone:
(571) 389-6056 
 Facsimile: (571) 389-6001 

Attention: Jonathan Weinberg 

E-mail: JWeinberg@evolenthealth.com 

with a copy (which shall not constitute notice to Evolent Health, Inc.) to: 

Cravath, Swaine & Moore LLP 

825 Eighth Avenue 
 New York, NY
10019 
 Telephone: (212) 474-1000 

Facsimile: (212) 474-3700 

Attention: William V. Fogg 

E-mail: wfogg@cravath.com 
 Each
Notice shall be deemed received on the date sent to the recipient thereof in accordance with this Section 4.02, if sent prior to 10:00 p.m. New York City time and such day is a Business Day; otherwise, such Notice shall be deemed not to
have been received until the next succeeding Business Day. 
 Section 4.03. Permitted Transferees. To the extent that a Class B
Member (or an applicable Permitted Transferee of such Class B Member) validly transfers after the date hereof any or all of its Class B common units and corresponding Class B Shares to a Permitted Transferee of such Person or to any other
Person in a transaction not in contravention of, and in accordance with, the Operating Agreement, then the transferee thereof shall have the right to execute and deliver a joinder to this Agreement, in form and substance reasonably satisfactory to
Evolent Health, Inc. Upon execution of any such joinder, such transferee shall, with respect to such transferred Class B common units and Class B Shares, be entitled to all of the rights and bound by each of the obligations applicable to the
relevant transferor hereunder; provided that the transferor shall remain entitled to all of the rights and bound by each of the obligations with respect to Class B common units and Class B Shares that were not so transferred. 

Section 4.04. Severability. The provisions of this Agreement shall be deemed severable and the invalidity or unenforceability of
any provision shall not affect the validity or enforceability of the other provisions hereof. If any provision of this Agreement, or the application thereof to any Person or entity or any circumstance, is found to be invalid or unenforceable in any
jurisdiction, (a) a suitable and equitable provision shall be substituted therefor in order to carry out, so far as may be valid and enforceable, the intent and purpose of such invalid or unenforceable provision and (b) the remainder of
this Agreement and the application of such provision to other Persons or circumstances shall not be affected by such invalidity or unenforceability, nor shall such invalidity or unenforceability affect the validity or enforceability of such
provision, or the application thereof, in any other jurisdiction. 

  
 10 








 Section 4.05. Counterparts. This Agreement may be executed (including by facsimile
transmission with counterpart pages) in one or more counterparts, each of which shall be deemed an original and all of which shall, taken together, be considered one and the same agreement, it being understood that all parties need not sign the same
counterpart. 
 Section 4.06. Entire Agreement; No Third Party Beneficiaries. This Agreement together with the Operating
Agreement, Stockholders Agreement and Registration Rights Agreement (a) constitutes the entire agreement and supersedes all other prior agreements, both written and oral, among the parties with respect to the subject matter hereof and
(b) is not intended to confer upon any Person, other than the parties hereto and their Permitted Transferees, any rights or remedies hereunder. 

Section 4.07. Further Assurances. Each party hereto shall execute, deliver, acknowledge and file such other documents and take
such further actions as may be reasonably requested from time to time by any other party hereto to give effect to and carry out the transactions contemplated herein. 

Section 4.08. Dispute Resolution. The provisions of Article 13 of the Operating Agreement are hereby incorporated herein in their
entirety. 
 Section 4.09. Governing Law. This Agreement and the rights of the parties hereunder will be governed by, construed
and enforced in accordance with the laws of the State of New York without regard to conflicts of law principles thereof. 

Section 4.10. Consent to Jurisdiction. The parties hereto agree that any suit, action or proceeding seeking to enforce any
provision of, or based on any matter arising out of or in connection with, this Agreement or the transactions contemplated hereby shall be brought and maintained exclusively in the United States District Court for the Southern District of New York
or the Supreme Court of the State of New York located in the County of New York. Each of the parties irrevocably consents to submit to the personal jurisdiction of such courts (and of the appropriate appellate courts therefrom) in any such suit,
action or proceeding. Process in any such suit, action or proceeding in such courts may be served, and shall be effective, on any party anywhere in the world, whether within or without the jurisdiction of any such court, by any of the methods
specified for the giving of Notices pursuant to Section 4.02. Each of the parties irrevocably waives, to the fullest extent permitted by law, any objection or defense that it may now or hereafter have based on venue, inconvenience of forum, the
lack of personal jurisdiction and the adequacy of service of process (as long as the party was provided Notice in accordance with the methods specified in Section 4.02) in any suit, action or proceeding brought in such courts. 

Section 4.11. WAIVER OF JURY TRIAL. EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY WAIVES ALL RIGHT TO TRIAL BY JURY IN ANY ACTION,
PROCEEDING OR COUNTERCLAIM ARISING OUT OF OR RELATING TO THIS AGREEMENT. 
 Section 4.12. Amendments; Waivers. (a) No
provision of this Agreement may be amended or waived unless such amendment or waiver is approved by a majority of the board of directors of Evolent Health, Inc. (including in such majority at least one director designee of each of The Advisory
Board, TPG and UPMC for so long as such stockholder has the right to designate at least one director to such board pursuant to the Stockholders Agreement), the Company and each of The Advisory Board and TPG (only to the extent they hold any Class B
common units) and their respective Permitted Transferees. 
 (b) No failure or delay by any party in exercising any right, power or
privilege hereunder shall operate as waiver thereof nor shall any single or partial exercise thereof preclude any other or further exercise thereof or the exercise of any other right, power or privilege. The rights and remedies herein provided shall
be cumulative and not exclusive of any rights or remedies provided by law. 

  
 11 








 Section 4.13. Assignment. Except as contemplated by Section 4.03 and except that
the rights to have a legend removed from a certificate representing Restricted Class A Shares in accordance with Section 3.02(b) shall be deemed automatically assigned in connection with any transfer not prohibited hereunder, neither this
Agreement nor any of the rights or obligations hereunder shall be assigned by any of the parties hereto without the prior written consent of the other parties. Subject to the preceding sentence, this Agreement will be binding upon, inure to the
benefit of and be enforceable by the parties and their respective successors, assigns and Permitted Transferees. 
 Section 4.14.
Tax Treatment. The parties to this Agreement intend that this Agreement shall be treated as part of the partnership agreement of the Company pursuant to Section 761(c) of the Code and Sections 1.704-1(b)(2)(ii)(h) and 1.761-1(c) of the
Treasury Regulations promulgated thereunder. Except as otherwise required by an applicable change in law: (a) the parties shall report an Exchange consummated hereunder as a taxable sale of Class B common units by a Class B Member to Evolent
Health, Inc., in which sale the consideration shall be the Class A Shares and any related payments made to such party under the Tax Receivables Agreement; and (b) no party shall take a contrary position on any income tax return, amendment
thereof or communication with a taxing authority. 
 Section 4.15. Effective Date. This Agreement shall become effective upon
the IPO and shall be of no force and effect prior to the IPO. 
 [Signature pages follow] 

  
 12 








 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed by their
respective authorized representatives as of the day and year first above written. 
  

			
	EVOLENT HEALTH, INC.
		
	By:		 /s/ Jonathan Weinberg

	Name:		Jonathan Weinberg
	Title:		General Counsel
	
	EVOLENT HEALTH LLC
		
	By:		 /s/ Jonathan Weinberg

	Name:		Jonathan Weinberg
	Title:		General Counsel



  
 [Signature Page to
Exchange Agreement] 








 
			
	TPG EAGLE HOLDINGS, L.P.
		
	By:		 /s/ Ronald Cami

	Name:		Ronald Cami
	Title:		Vice President



  
 [Signature Page to
Exchange Agreement] 








 
			
	THE ADVISORY BOARD COMPANY
		
	By:		 /s/ Evan Farber

	Name:		Evan Farber
	Title:		General Counsel and Corporate Secretary



  
 [Signature Page to
Exchange Agreement] 








 
			
	PTOLEMY CAPITAL, LLC
		
	By:		 /s/ Mitchell Otolski

	Name:		Mitchell Otolski
	Title:		Agent



  
 [Signature Page to
Exchange Agreement] 








 Exhibit A 
  

									
	 	  	Immediately Following IPO	 
	 	  	Number of
Class B
Common
Units
Owned	 	  	Number
of
Class B
Shares
Owned	 
	 Name and Address of Class B Member
	  				  			
	 TPG Eagle Holdings, L.P.

301 Commerce Street, Suite 3300

Fort Worth, Texas 76102

Facsimile: (817) 871-4001
	  	 	11,289,668	  	  	 	11,289,668	  
			
	 The Advisory Board Company

2445 M Street, NW

Washington, D.C. 20037

Facsimile: (202) 266-5700
	  	 	5,208,688	  	  	 	5,208,688	  
			
	 Ptolemy Capital, LLC

1250 Prospect St, Suite 200

La Jolla, California 92037

Attention: Michael R. Stone

Facsimile: (858) 551-1175
	  	 	1,026,240	  	  	 	1,026,240